SANOREX
LOE ApproachingNDAORALTABLET
Approved
Jun 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SANOREX is an oral small-molecule tablet approved in 1973 by Novartis with an unknown mechanism of action and indication profile. The product's therapeutic area and patient population cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial data; team likely focused on generic transition planning or lifecycle extension strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SANOREX has zero linked job openings, indicating minimal active hiring or career development opportunities. This product is in late-stage lifecycle with likely team consolidation or realignment ahead.
Brand ManagerMarket Access
Worked on SANOREX at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.